Prof. Dr. Bülent Karabulut
Is this your profile? Claim it and verify your details.
Claim profileThe CV details on this page were translated automatically from the language of the source. See the original
Person ↔ Disease
Which diseases does this doctor work on?
-
Colorectal Neoplasms 15 publicationsSource: OpenAlex / PubMed MeSHView publications
- Breast Neoplasms 14 publications
- Prostatic Neoplasms 13 publications
- Ovarian Neoplasms 10 publications
- Adenocarcinoma 6 publications
- Rectal Neoplasms 5 publications
- Gastrointestinal Neoplasms 4 publications
- Colonic Neoplasms 4 publications
- Obesity 4 publications
- Neoplasms 4 publications
- Stomach Neoplasms 3 publications
- Pancreatic Neoplasms 3 publications
- Neoplasms, Hormone-Dependent 3 publications
- Carcinoma, Renal Cell 2 publications
- Kidney Neoplasms 2 publications
- Hypertension 2 publications
- Hematologic Diseases 2 publications
- Liver Neoplasms 2 publications
- Bone Neoplasms 2 publications
- Cystadenocarcinoma, Serous 2 publications
- Carcinoma, Small Cell 2 publications
Person ↔ Disease
Which topics does this doctor work on?
Medical areas of interest stated by the doctor on the institution profile. Source: acibadem.com.tr.
- Ovarian cancer
- Gynaecological tumours and cancers (uterine, cervical, ovarian cancer, etc.)
- Pancreatic cancer
- Oesophageal cancer
- Gastric cancer
- Bladder cancer
- Breast cancer
- Gallbladder and biliary tract cancers
- Peritoneal cancer
- Liver cancer
- Endometrial cancer
- Kidney cancer
- Lung and pleural cancers (mesothelioma) and other thoracic cancers
- Head and neck cancers
- Colorectal cancer (colon and rectal cancer)
- Gallbladder cancer
- Lung cancer
- Colon (large bowel) cancer
CV
Education and experience
Experience
- 2023Acıbadem Healthcare Groupacibadem.com.tr
- 1997Research in the medical oncology cell research laboratory, Ege University Faculty of Medicineacibadem.com.tr
- ExperienceKent Hastanesi (private hospital), Kent Oncology Centre: General Coordinator and Medical Oncologistacibadem.com.tr
Education
- 2011Professorshipacibadem.com.tr
- 2006Associate Professorshipacibadem.com.tr
- 2001Ege University Faculty of Medicine, Medical Oncology (subspecialty)acibadem.com.tr
- 1999Ege University Faculty of Medicine, Internal Medicine (specialty training)acibadem.com.tr
- 1993Ege University Faculty of Medicine (medical degree)acibadem.com.tr
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyMedical Oncologyacibadem.com.trFrom source
- InstitutionAcıbadem Kent Hastanesi (İzmir)acibadem.com.trFrom source
- Area of workColorectal NeoplasmsExtracted from 15 publications · Model version —From source
- Publications196 publicationsOpenAlex, ORCIDFrom source
- ORCID0000-0002-1949-8334ORCIDFrom source
- Last synchronised4 November 2026 20:48https://www.acibadem.com.tr/doktor/bulent-karabulut/acibadem.com.tr
Scientific work
Publications on Colorectal Neoplasms
-
Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry
Anadolu Kliniği Tıp Bilimleri Dergisi, 2026
DOI 10.21673/anadoluklin.1675424 Open-access full textSource: OpenAlex
-
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study
Cancers, 2026
DOI 10.3390/cancers18121979 PMID 42352512 Open-access full textSource: OpenAlex
-
Prognostic and Treatment-Specific Predictive Implications of HER2 Expression in RAS Wild-Type Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Study
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15103979 PMID 42194940 Open-access full textSource: OpenAlex
-
Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature
Clinical Genitourinary Cancer, 2026
DOI 10.1016/j.clgc.2026.102594 PMID 42349378 Source: OpenAlex
-
Clinical Characteristics, Treatment Patterns, and Survival Outcomes of Right-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer: A Real-World Multicenter Cohort Study
Clinics and Practice, 2026
DOI 10.3390/clinpract16090158 PMID 42783081 Open-access full textSource: OpenAlex
-
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Current Oncology, 2026
DOI 10.3390/curroncol33060365 PMID 42346265 Open-access full textSource: OpenAlex
-
Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15020467 PMID 41598406 Open-access full textSource: ORCID
-
Association Between Preoperative Albumin-to-Globulin Ratio (AGR) and Recurrence-Free Survival in High-Risk Resected Cutaneous Melanoma
Eurasian Journal of Medical Investigation, 2026
DOI 10.14744/ejmi.2612540 Source: ORCID
-
Impact of oral nutritional support adherence on muscle strength, body composition, and general health status in gastrointestinal cancer patients: ONMUS study
Nutrition, 2026
DOI 10.1016/j.nut.2025.113029 PMID 41455457 1 citation (Europe PMC) Source: ORCID
-
Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study
Targeted Oncology, 2026
DOI 10.1007/s11523-026-01261-w PMID 42907609 Source: OpenAlex